Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and gemtuzumab ozogamicin,
work in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
more cancer cells.
PURPOSE: This phase II trial is studying how well giving arsenic trioxide together with
gemtuzumab ozogamicin works in treating patients with advanced myelodysplastic syndromes.
Phase:
Phase 2
Details
Lead Sponsor:
The Cleveland Clinic
Collaborators:
National Cancer Institute (NCI) University of Michigan